Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kronos Bio (KRON)
NASDAQ:KRON
KRON Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.69 - $1.60
Previous CloseN/A
Volume122.28K
Average Volume (3M)216.22K
Market Cap
$61.55M
Enterprise Value-$38.75M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Mar 19, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding60,340,920
10 Day Avg. Volume174,629
30 Day Avg. Volume216,222
Standard Deviation0.19
R-Squared0.19
Alpha-0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.23
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.16
Enterprise Value/Ebitda0.51
Forecast
1Y Price Target
$1.00Price Target Upside-1.96% Downside
Rating ConsensusHold
Number of Analyst Covering0
---
Kronos Bio News
PremiumCompany Announcements
Kronos Bio Ends Collaboration with Genentech and Roche
PremiumCompany Announcements
Kronos Bio Restructures Workforce and Leadership
---
Bulls Say, Bears Say
Bulls Say
Cost ManagementR&D and SG&A expenses were lower than prior estimates, indicating improved cost management by Kronos.
Financial PerformanceKronos recorded a net loss of $0.27 per share, which was narrower than the prior estimate, reflecting better-than-expected financial performance.
Financial StabilityKronos ended with $136.6M in cash, cash equivalents, and marketable securities, ensuring a solid operational runway.
Bears Say
Clinical Development ChallengesKronos announced the decision to halt clinical development of its lead candidate CDK9i KB-0742 due to an unfavorable safety-benefit profile.
Safety ConcernsOut of 7 enrolled PROC patients, 5 exhibited neurological events ranging from Grade 1-3 in severity, leading to treatment discontinuation for some.
Strategic UncertaintyKronos is exploring strategic alternatives after halting istisociclib development, creating uncertainty about the company's future direction.
---
Ownership Overview
27.67% Insiders
4.06% Mutual Funds
17.62% Other Institutional Investors
47.35% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KRON FAQ
What was Kronos Bio’s price range in the past 12 months?
Kronos Bio lowest stock price was $0.69 and its highest was $1.60 in the past 12 months.
What is Kronos Bio’s market cap?
Kronos Bio’s market cap is $61.55M.
When is Kronos Bio’s upcoming earnings report date?
Kronos Bio’s upcoming earnings report date is Mar 19, 2025 which is in 26 days.
How were Kronos Bio’s earnings last quarter?
Kronos Bio released its earnings results on Nov 13, 2024. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.278 by $0.048.
Is Kronos Bio overvalued?
According to Wall Street analysts Kronos Bio’s price is currently Overvalued.
Does Kronos Bio pay dividends?
Kronos Bio does not currently pay dividends.
What is Kronos Bio’s EPS estimate?
Kronos Bio’s EPS estimate is -0.29.
How many shares outstanding does Kronos Bio have?
Kronos Bio has 60,340,920 shares outstanding.
What happened to Kronos Bio’s price movement after its last earnings report?
Kronos Bio reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.278. Following the earnings report the stock price went down -3.409%.
Which hedge fund is a major shareholder of Kronos Bio?
Currently, no hedge funds are holding shares in KRON
---
Kronos Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.00 (-1.96% Downside)
$1.00 (-1.96% Downside)
Blogger Sentiment
Bullish
KRON Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.7%
Last 30 Days ▲ 4.3%
Last 30 Days ▲ 4.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.00%
12-Months-Change
Fundamentals
Return on Equity
-59.08%
Trailing 12-Months
Asset Growth
-36.96%
Trailing 12-Months
Company Description
Kronos Bio
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription.
---
KRON Stock 12 Month Forecast
Average Price Target
$1.00
▼(-1.96% Downside)
Technical Analysis
Fate Therapeutics
―
Adaptimmune Therapeutics
―
Kura Oncology
―
X4 Pharmaceuticals
―
IGM Biosciences
―
Best Analysts Covering KRON
1 Year
1 Year Success Rate
1/14 ratings generated profit
1 Year Average Return
-28.80%
reiterated a buy rating 6 months ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 7.14% of your transactions generating a profit, with an average return of -28.80% per trade.
---